Compile Data Set for Download or QSAR
maximum 50k data
Found 605 with Last Name = 'solovay' and Initial = 'c'
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531223((R)-2-(4-Methyl-6-((1-methylpiperidin-3-yl)amino)p...)
Affinity DataIC50:  0.400nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531296(US11208399, Example 53)
Affinity DataIC50:  0.400nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50500363(CHEMBL3747481)
Affinity DataIC50:  0.400nMAssay Description:Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BaF3 cells using poly(Glu,Tyr) as substrate after 10 mins by scintillation counting a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134505(US8846656, 21-D)
Affinity DataIC50:  0.5nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134531(US8846656, 23-I)
Affinity DataIC50:  0.5nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50500371(CHEMBL3746941)
Affinity DataIC50:  0.5nMAssay Description:Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BaF3 cells using poly(Glu,Tyr) as substrate after 10 mins by scintillation counting a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531253(US11208399, Example 12)
Affinity DataIC50:  0.600nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50270431(CHEMBL4076909)
Affinity DataIC50:  0.700nMAssay Description:Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531331(US11208399, Example 82)
Affinity DataIC50:  0.700nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531289(US11208399, Example 48)
Affinity DataIC50:  0.800nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531332(US11208399, Example 83a)
Affinity DataIC50:  0.800nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531319(US11208399, Example 71)
Affinity DataIC50:  0.800nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531220((R)-2-(6-((1-Ethylpiperidin-3-yl)amino)pyridazin-3...)
Affinity DataIC50:  0.800nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531288(US11208399, Example 47)
Affinity DataIC50:  0.800nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50270424(CHEMBL3746776)
Affinity DataIC50:  0.900nMAssay Description:Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50500370(CHEMBL3746273)
Affinity DataIC50:  0.900nMAssay Description:Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BaF3 cells using poly(Glu,Tyr) as substrate after 10 mins by scintillation counting a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531230(US11208399, Example 6)
Affinity DataIC50:  0.900nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50270424(CHEMBL3746776)
Affinity DataIC50:  0.900nMAssay Description:Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BaF3 cells using poly(Glu,Tyr) as substrate after 10 mins by scintillation counting a...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134511(US8846656, 21-Q)
Affinity DataIC50:  1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134519(US8846656, 21-AH)
Affinity DataIC50:  1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134518(US8846656, 21-AG)
Affinity DataIC50:  1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134580(US8846656, 56-C)
Affinity DataIC50:  1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134582(US8846656, 56-F)
Affinity DataIC50:  1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134577(US8846656, 55-M)
Affinity DataIC50:  1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134569(US8846656, 52-C)
Affinity DataIC50:  1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134520(US8846656, 21-AI)
Affinity DataIC50:  1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134523(US8846656, 21-AL)
Affinity DataIC50:  1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134586(US8846656, 65-A)
Affinity DataIC50:  1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134596(US8846656, 69-L)
Affinity DataIC50:  1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134589(US8846656, 65-I)
Affinity DataIC50:  1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134524(US8846656, 21-AM)
Affinity DataIC50:  1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134574(US8846656, 55-I)
Affinity DataIC50:  1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134500(US8846656, 19-AF)
Affinity DataIC50:  1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50500377(CHEMBL3747084)
Affinity DataIC50:  1nMAssay Description:Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BaF3 cells using poly(Glu,Tyr) as substrate after 10 mins by scintillation counting a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134512(US8846656, 21-R)
Affinity DataIC50:  1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134530(US8846656, 23-H)
Affinity DataIC50:  1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531254(US11208399, Example 13)
Affinity DataIC50:  1.20nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50270430(CHEMBL4077373)
Affinity DataIC50:  1.30nMAssay Description:Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50270425(CHEMBL4080062)
Affinity DataIC50:  1.30nMAssay Description:Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531337(3-Methyl-2-(6-(((1R,2R,5R)-8-methyl-8-azabicyclo[3...)
Affinity DataIC50:  1.30nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531252(US11208399, Example 11)
Affinity DataIC50:  1.30nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531354(2-(6-(((3S, 5S)-5-Fluoro-1-methylpiperidin-3-yl)am...)
Affinity DataIC50:  1.60nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531291(US11208399, Example 49)
Affinity DataIC50:  1.60nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50270439(CHEMBL4104297)
Affinity DataIC50:  1.70nMAssay Description:Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531339(2-(6-(((1S,2S,5S)-8-(2-Hydroxyethyl)-8-azabicyclo[...)
Affinity DataIC50:  1.80nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531364((R)-2-(6-((1-Ethylpiperidin-3-yl)amino)-5-methylpy...)
Affinity DataIC50:  1.90nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 beta(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM531232(US11208399, Example 7)
Affinity DataIC50:  1.90nMAssay Description:Monocytic THP-1 cells (ATCC: TIB-202) were maintained according to providers' instructions in RPMI media (RPMI/Hepes+10% fetal bovine serum+Sodiu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134509(US8846656, 21-N)
Affinity DataIC50:  2nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134479(US8846656, 17-AM)
Affinity DataIC50:  2nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134572(US8846656, 55-G)
Affinity DataIC50:  2nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
Displayed 1 to 50 (of 605 total ) | Next | Last >>
Jump to: